National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- (-) Cancer (7)
- Cancer: Colorectal Cancer (2)
- Cancer: Prostate Cancer (2)
- Elderly (1)
- Evidence-Based Practice (1)
- Genetics (1)
- Healthcare Delivery (1)
- Healthcare Utilization (1)
- Hospitalization (1)
- Medication (1)
- (-) Mortality (7)
- Outcomes (3)
- Patient-Centered Outcomes Research (1)
- Quality of Life (1)
- Registries (1)
- Risk (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 7 of 7 Research Studies DisplayedBeg MS, Gupta A, Sher D
Impact of concurrent medication use on pancreatic cancer survival-SEER-Medicare analysis.
Researchers examined the association of several medication classes on pancreatic cancer survival, using data from the Surveillance, Epidemiology, and End Results-Medicare database. They found that the use of beta-blockers, heparin, insulin, and warfarin were associated with improved survival in patients with pancreatic cancer, whereas metformin, thiazolidinedione, statin, and combination therapies were not. The authors recommended additional studies to validate these findings in the clinical setting.
AHRQ-funded; HS022418.
Citation: Beg MS, Gupta A, Sher D .
Impact of concurrent medication use on pancreatic cancer survival-SEER-Medicare analysis.
Impact of concurrent medication use on pancreatic cancer survival-SEER-Medicare analysis..
Keywords: Cancer, Medication, Mortality, Outcomes, Patient-Centered Outcomes Research, Evidence-Based Practice
Banerjee M, Reyes-Gastelum D, Haymart MR
Treatment-free survival in patients with differentiated thyroid cancer.
This study evaluated treatment-free survival for 9273 patients who had differentiated thyroid cancer between 1998 and 2012. Most patients (75%) were female and median age at time of diagnosis was 69 years. The data was evaluated from the SEERS Program-Medicare registry. Five prognostic groups were identified and 5-year survival rates ranged from 96% down to 52%, and 10-year survival rates from 94% down to 39%. Factors for predicting survival rates were stage, tumor size, and treatment with radioactive iodine.
AHRQ-funded; HS024512.
Citation: Banerjee M, Reyes-Gastelum D, Haymart MR .
Treatment-free survival in patients with differentiated thyroid cancer.
J Clin Endocrinol Metab 2018 Jul;103(7):2720-27. doi: 10.1210/jc.2018-00511..
Keywords: Cancer, Mortality, Outcomes
Haymart MR
Is BRAF V600E mutation the explanation for age-associated mortality risk in patients with papillary thyroid cancer?
In this editorial, the author discusses an article appearing within the same issue. She states that the general hypothesis that age-related differences in mortality could be linked to underlying pathogenesis and specifically to oncogenic alterations is probable. She recommends confirmatory studies and concludes that this area of investigation offers potential opportunities to tailor prognostication further through a better understanding of pathogenesis.
AHRQ-funded; HS024512.
Citation: Haymart MR .
Is BRAF V600E mutation the explanation for age-associated mortality risk in patients with papillary thyroid cancer?
J Clin Oncol 2018 Feb 10;36(5):433-34. doi: 10.1200/jco.2017.76.2583..
Keywords: Cancer, Genetics, Mortality, Risk
Banerjee M, Muenz DG, Worden FP
Conditional survival in patients with thyroid cancer.
This study used data from Surveillance, Epidemiology, and End Results (SEER) registry to determine conditional 5-year disease-specific survival based on patient age, gender, and stage. It found that patients with localized thyroid cancer have excellent conditional 5-year survival, irrespective of where they are in their survivorship phase. In addition, patients with regional thyroid cancer have relatively stable conditional 5-year survival.
AHRQ-funded; HS020937.
Citation: Banerjee M, Muenz DG, Worden FP .
Conditional survival in patients with thyroid cancer.
Thyroid 2014 Dec;24(12):1784-9. doi: 10.1089/thy.2014.0264..
Keywords: Cancer, Mortality, Outcomes, Registries
Rabin BA, Ellis JL, Steiner JF
Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC.
The authors described health service utilization patterns of subgroups of prostate cancer and colorectal cancer (CRC) patients with different relative probabilities of dying of their cancer or other conditions. They found that although a new diagnosis of cancer increased utilization of cancer-related services for an extended time period, the timing of cancer diagnosis did not appear to affect other types of utilization.
AHRQ-funded; HS019520.
Citation: Rabin BA, Ellis JL, Steiner JF .
Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC.
J Natl Cancer Inst Monogr 2014 Nov;2014(49):275-81. doi: 10.1093/jncimonographs/lgu023.
.
.
Keywords: Cancer: Prostate Cancer, Cancer: Colorectal Cancer, Cancer, Healthcare Utilization, Mortality, Healthcare Delivery
Arvold ND, Wang Y, Zigler C
Hospitalization burden and survival among older glioblastoma patients.
The researchers performed a retrospective cohort study among patients aged 65 years and older with glioblastoma diagnosed between 1999 and 2007. They found that higher comorbidity score and black race were associated with an increased risk of being hospitalized for at least 25% of remaining life, whereas radiation, temozolomide, and extensive surgery were associated with a decreased risk.
AHRQ-funded; HS021991.
Citation: Arvold ND, Wang Y, Zigler C .
Hospitalization burden and survival among older glioblastoma patients.
Neuro Oncol 2014 Nov;16(11):1530-40. doi: 10.1093/neuonc/nou060.
.
.
Keywords: Cancer, Elderly, Hospitalization, Mortality, Quality of Life
Feuer EJ, Rabin BA, Zou Z
The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.
The researchers externally validate the nomograms for prostate and colorectal cancer using data from Kaiser Permanente Colorado. Their results indicated that the colorectal and prostate cancer nomograms are reliable tools for physicians and patients to use to obtain information on prognosis and assist in establishing priorities for both treatment of the cancer and other conditions, particularly when a patient is elderly and/or has significant comorbidities.
AHRQ-funded; HS019520.
Citation: Feuer EJ, Rabin BA, Zou Z .
The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.
J Natl Cancer Inst Monogr 2014 Nov;2014(49):265-74. doi: 10.1093/jncimonographs/lgu021.
.
.
Keywords: Cancer: Colorectal Cancer, Cancer: Prostate Cancer, Cancer, Mortality